NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-10-30 18:02இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Fresita Proteins Q2 PAT Falls 65% YoY to Rs 13.95 Lakh; Proposes Registered Office Shift to Gujarat
Fresita Proteins reported standalone revenue from operations of Rs 81.03 lakh for Q2 FY27 (ended September 30, 2026), marking an 81% decline from Rs 430.38 lakh in Q2 FY26 and a steep drop from Rs 1,299.30 lakh in Q1 FY27. Net profit for the quarter stood at Rs 13.95 lakh, down 65.5% YoY compared to Rs 40.46 lakh in the prior-year period. Notably, the company reported operating in only one segment: 'Renewable Energy Sector Solar Module Products'. The Board also approved shifting its registered office from Alwar, Rajasthan to Rajkot, Gujarat, subject to shareholder approval.
உச்சம் நம்பிக்கை
என்ன மாறியதுFresita Proteins reported its Q2 FY27 financial results showing a sharp revenue contraction and approved the relocation of its registered office to Gujarat.
ஏன் இது முக்கியம்Quarterly revenues dropped significantly compared to the prior quarter, and the note confirms operations have transitioned entirely into renewable energy solar module products.
Q2 FY27 Revenue: 81.03 LakhsQ2 FY27 Net Profit: 13.95 LakhsH1 FY27 Net Profit: 179.91 LakhsShort Term Loans as of 30.09.2026: 7,258.96 LakhsTrade Receivables as of 30.09.2026: 2,477.21 Lakhs
📅 குறுகிய காலம்The sharp sequential and YoY drop in top-line and net profit is likely to weigh on near-term market sentiment.
📈 நீண்ட காலம்Business sustainability depends on securing steady orders within its solar module segment and converting its large short-term loan assets and receivables into operating cash flows.
⚠ அபாய எச்சரிக்கைகள்
Lumpy and volatile revenue trends
Substantial concentration of assets in Short Term Loans (Rs 72.59 cr vs Rs 88 cr equity)
High trade receivables relative to quarterly revenue
👀 கவனிக்க வேண்டியவை
Track the upcoming shareholder vote on shifting the registered office and watch for consistency in solar module trading revenues and cash flow recovery in subsequent quarters.
Fresita Proteins Issues Letter of Offer for ₹89.76 Cr Rights Issue at ₹120/share
Fresita Proteins Ltd (formerly Sarda Proteins Ltd) has filed its Letter of Offer for a Rights Issue to raise up to ₹89.76 crore. The company is offering up to 74,79,917 shares at ₹120 per share (face value ₹10 plus premium of ₹110) in the ratio of 5 rights shares for every 6 existing shares held on the record date of October 30, 2026. The proposed fundraise is massive relative to the company's size, representing ~117% of its current market capitalization of ₹77 crore. The issue opens on November 12, 2026, and closes on November 26, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுFiling of the formal Letter of Offer detailing final terms and schedule for the ₹89.76 crore Rights Issue.
ஏன் இது முக்கியம்The fundraise of ₹89.76 crore is larger than the entire current market cap of ₹77 crore, resulting in substantial equity dilution and capital injection.
வெளியீட்டு அளவு: ₹8975.90 லட்சம்வெளியீட்டு விலை: ₹120/- per shareRights ratio: 5:6வழங்கப்பட்ட பங்குகள்: 74,79,917Issue size vs Market Cap: ~117%
📅 குறுகிய காலம்Trading of Rights Entitlements (RE) and price adjustments around the ex-rights/record date will drive near-term volatility.
📈 நீண்ட காலம்Capital deployment will drastically reshape the company's balance sheet, but substantial dilution will impact per-share metrics unless proceeds drive proportional earnings growth.
⚠ அபாய எச்சரிக்கைகள்
High equity dilution (~45.5% expansion of capital base if fully subscribed)
Issue size exceeds total market cap, creating subscription and capital allocation execution risks
👀 கவனிக்க வேண்டியவை
Eligible shareholders should track the credit of Rights Entitlements by November 2, 2026, and note the last date for on-market renunciation on November 20, 2026.
Fresita Proteins Approves ₹89.76 Cr Rights Issue at ₹120/Share (5:6 Ratio)
Fresita Proteins has finalized terms for a Rights Issue aggregating up to ₹89.76 crore by offering 74,79,917 equity shares at ₹120 per share (including ₹110 premium). The issue is structured in an entitlement ratio of 5 rights equity shares for every 6 shares held, with a Record Date set for October 30, 2026. The proposed fundraise is massive relative to the company's existing scale, representing ~117% of its current market cap of ₹77 crore. The subscription window opens on November 12, 2026, and closes on November 26, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe Rights Issue Committee has approved specific pricing, entitlement ratio, schedule, and record date for its ₹89.76 crore rights issue.
ஏன் இது முக்கியம்The capital raise of ~₹89.8 crore is larger than the company's current market cap (~₹77 crore) and will expand the equity base by ~83.3%, resulting in substantial dilution unless existing shareholders participate.
Issue Size: ₹89,75,90,000Issue Price: ₹120/- per Rights Equity ShareIssue vs Market Cap: ~116.6%Rights Entitlement Ratio: 5:6ரெக்கார்ட் தேதி: வெள்ளி, அக்டோபர் 30, 2026
📅 குறுகிய காலம்Shares may see volatility heading toward the October 30 record date as investors evaluate the 5:6 entitlement ratio and pricing relative to spot levels.
📈 நீண்ட காலம்If successfully subscribed, the ₹89.76 crore infusion could significantly alter the balance sheet of the company (TTM revenue ₹18 crore), depending on capital deployment.
⚠ அபாய எச்சரிக்கைகள்
Heavy equity dilution of ~83.3% upon full subscription
Issue price (₹120) is close to the market price (₹124.2), leaving minimal margin of safety for participants
Deployment details and end-use of proceeds need scrutiny in the Letter of Offer
👀 கவனிக்க வேண்டியவை
Track the ex-rights trading ahead of the October 30, 2026 record date and monitor the deployment plan in the Letter of Offer when dispatched.
Fresita Proteins Rights Issue Committee to Meet on Oct 26 to Finalize Up to ₹90 Cr Issue Terms
Fresita Proteins Limited has scheduled a Rights Issue Committee meeting on October 26, 2026, to determine the final terms of its proposed rights issue. The fundraise was previously approved by the Board on August 5, 2026, for an amount not exceeding ₹90 Crore. The committee will decide the issue price, entitlement ratio, record date, and issue timing. The ₹90 Crore size is massive compared to the company's current market capitalization of ₹77 Crore (117%) and TTM revenue of ₹18 Crore (500%).
உச்சம் நம்பிக்கை
என்ன மாறியதுFresita Proteins called a Rights Issue Committee meeting for October 26, 2026, to fix the specific terms of its previously approved rights issue.
ஏன் இது முக்கியம்At up to ₹90 Crore, the planned fundraise exceeds the company's total market cap (₹77 Crore) and dwarfs its TTM revenue (₹18 Crore), implying severe equity dilution and a significant shift in capital structure.
Max Rights Issue size: Rs. 90 CroreIssue size vs Market Cap: ~117%Issue size vs TTM Revenue: ~500%Committee meeting date: அக்டோபர் 26, 2026ஒரு பங்கின் முக மதிப்பு: ₹10 each
📅 குறுகிய காலம்Volatility may increase around the announcement of the rights issue price, entitlement ratio, and record date on October 26, 2026.
📈 நீண்ட காலம்If successfully raised, ₹90 Crore could fund significant scale or balance sheet expansion, but existing shareholders face substantial dilution depending on the rights issue pricing.
⚠ அபாய எச்சரிக்கைகள்
Massive potential equity dilution as the issue size exceeds the current market cap
Execution risk regarding capital deployment for a micro-cap company with historical revenue volatility
👀 கவனிக்க வேண்டியவை
Track the outcome of the October 26 meeting for the issue price, discount to current market price, dilution ratio, and the stated deployment plans for the ₹90 Crore proceeds.
₹100 Cr Rights Issue Approved by Sarda Proteins; Director Resigns
Sarda Proteins has approved a significant fundraise through a Rights Issue of equity shares for an amount not exceeding ₹100 crore. This proposed issue size is substantial, representing approximately 116% of the company's reported net worth of ₹86 crore. Simultaneously, the company announced the resignation of Non-Executive Director Mr. Gunvantray Jayantilal Zaladi, effective August 5, 2026. A Rights Issue Committee has been formed to oversee the process, including the filing of the Draft Letter of Offer with SEBI.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has initiated a major capital raising process and experienced a change in its board of directors.
ஏன் இது முக்கியம்A ₹100 crore fundraise is transformative for a company with a quarterly revenue of just ₹0.65 crore (Mar 2026), suggesting a potential major expansion or shift in business scale.
Rights Issue Size: ₹100 CroreNet Worth: ₹86 கோடிFundraise vs Net Worth: ~116%Mar 2026 Revenue: ₹0.65 கோடிDirector Resignation Date: ஆகஸ்ட் 05, 2026
📅 குறுகிய காலம்The stock may experience volatility as the market digests the scale of the rights issue and awaits pricing and ratio details.
📈 நீண்ட காலம்If the ₹100 crore is deployed effectively into revenue-generating assets, it could structurally re-rate the company from its current low-revenue base.
⚠ அபாய எச்சரிக்கைகள்
Significant equity dilution
Execution risk for a fundraise larger than current net worth
Low current revenue base relative to fundraise size
👀 கவனிக்க வேண்டியவை
Investors should closely monitor the Draft Letter of Offer (DLOF) to understand the specific utilization of the ₹100 crore proceeds and the resulting equity dilution.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Sarda Proteins Ltd FY26 Net Profit at Rs 0.45 Cr; Revenue drops 32% YoY to Rs 16.51 Cr
Sarda Proteins Ltd has issued revised audited financial results for FY26 to correct clerical errors involving interest income and the reclassification of share warrants as equity. For the full year ended March 31, 2026, the company reported a total revenue of Rs 16.51 Cr, representing a 31.7% decline from Rs 24.19 Cr in FY25. Despite the revenue drop, net profit improved to Rs 0.45 Cr from a near-break-even Rs 0.005 Cr in the previous year. The Q4 FY26 performance was bolstered by other income of Rs 24.36 Lakhs, leading to a quarterly profit of Rs 0.686 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company revised its previously submitted FY26 results to correctly account for interest income and reclassify share warrants as equity capital.
ஏன் இது முக்கியம்While the revision is clerical, the underlying financials show a significant contraction in business scale (revenue down 32%) despite an improvement in absolute profit margins from a very low base.
FY26 Total Revenue: Rs 16.51 கோடிFY25 Total Revenue: Rs 24.19 கோடிFY26 Net Profit: Rs 0.45 கோடிEquity Capital Increase: 520%FY26 Basic EPS: Rs 0.51
📅 குறுகிய காலம்The stock may remain neutral as the revision is non-material to the bottom line, though the revenue decline is a fundamental concern.
📈 நீண்ட காலம்The company's small scale and volatile revenue stream suggest limited structural significance unless it can leverage its debt-free status to expand operations.
High reliance on 'Other Income' for quarterly profitability
Small absolute scale of operations
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to stabilize its top-line revenue, which saw a sharp decline this fiscal year. The impact of the warrant-to-equity conversion on future earnings per share (EPS) dilution should also be watched.
Sarda Proteins to consider fundraise via Equity/QIP/Rights Issue on August 05, 2026
Sarda Proteins has scheduled a Board Meeting for August 05, 2026, to evaluate various fund-raising options. The company is considering multiple instruments including equity shares, convertible bonds, debentures, and warrants. Potential routes for this capital infusion include rights issues, private placements, preferential issues, or Qualified Institutions Placements (QIP). As of the announcement on July 31, 2026, the specific quantum of funds to be raised and the intended use of proceeds remain undisclosed.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has moved from a routine operational phase to actively seeking capital infusion through various equity-linked instruments.
ஏன் இது முக்கியம்A fundraise is a significant event for a small-cap company in the edible oil sector, as it can either signal aggressive growth plans or a need to strengthen the balance sheet, though it typically involves equity dilution.
📅 குறுகிய காலம்The stock price may experience volatility in the days leading up to the August 05 meeting as the market anticipates the size and terms of the fundraise.
📈 நீண்ட காலம்The long-term impact depends on the deployment of funds; capital used for capacity expansion in the edible oil industry could be a structural positive, whereas use for working capital may be neutral.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution risk for existing shareholders
Uncertainty regarding the pricing and mode of the fundraise
👀 கவனிக்க வேண்டியவை
Investors should watch for the post-meeting disclosure on August 05 to identify the total fundraise amount, the issue price, and whether the capital is intended for debt repayment or capacity expansion.
Sarda Proteins Reports ₹1.66 Cr PAT in Q1 FY27; Pivots to Solar Cell Products Segment
Sarda Proteins reported a sharp turnaround in Q1 FY27, posting a net profit of ₹165.97 Lakhs compared to a loss of ₹49.34 Lakhs in the year-ago period. Revenue from operations grew 18.6% YoY to ₹1,299.30 Lakhs, while 'Other Income' saw a massive spike to ₹548.10 Lakhs. Crucially, the company disclosed it now operates solely in the 'Renewable Energy Sector Solar Cell Products' segment, a major shift from its historical edible oil focus. The board also established a new corporate office in Rajkot and appointed an Independent Women Director.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has turned profitable and officially pivoted its business model from edible oils to the renewable energy/solar cell sector.
ஏன் இது முக்கியம்The shift to the solar sector represents a fundamental change in the company's risk-reward profile and growth potential, moving away from low-margin edible oils.
Q1 FY27 Revenue: ₹1,299.30 லட்சம்Q1 FY27 Net Profit: ₹165.97 லட்சம்பிற வருமானம்: ₹548.10 லட்சம்Basic EPS: ₹1.85Paid up Equity Capital: ₹89.759 லட்சம்
📅 குறுகிய காலம்The stock may see positive momentum due to the turnaround from loss to profit and the entry into the high-interest solar sector.
📈 நீண்ட காலம்The long-term outlook depends on the company's ability to scale its new solar cell operations and maintain margins without relying on 'Other Income'.
⚠ அபாய எச்சரிக்கைகள்
High reliance on Other Income for current profitability
Business transition risk into a new industry (Solar)
👀 கவனிக்க வேண்டியவை
Investors should monitor the sustainability of the new solar cell business segment and investigate the source of the ₹5.48 Cr 'Other Income' which drove much of this quarter's profit.
₹165.97 Lakhs Net Profit: Sarda Proteins Reports Turnaround in Q1 FY27 Results
Sarda Proteins reported a significant turnaround in Q1 FY27, posting a net profit of ₹165.97 Lakhs compared to a loss of ₹49.34 Lakhs in the same quarter last year. Revenue from operations grew 18.6% YoY to ₹1,299.30 Lakhs, while total revenue reached ₹1,847.40 Lakhs, significantly aided by ₹548.10 Lakhs in other income. The company also announced the establishment of a new corporate office in Rajkot, Gujarat, and the appointment of an Independent Women Director for a 5-year term. Notably, the company now identifies its primary segment as 'Renewable Energy Sector Solar Cell Products'.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned from a loss-making position to profitability and officially declared its business segment as Renewable Energy/Solar Cell Products while expanding its corporate presence to Gujarat.
ஏன் இது முக்கியம்The turnaround and segment shift suggest a major strategic pivot; the establishment of a Gujarat office may indicate a focus on the regional renewable energy hub.
📅 குறுகிய காலம்The stock may see positive momentum due to the sharp turnaround in profitability and revenue growth reported for the June quarter.
📈 நீண்ட காலம்The structural shift into the Renewable Energy sector is significant; long-term value will depend on the company's ability to generate consistent operating margins in this new segment.
⚠ அபாய எச்சரிக்கைகள்
High reliance on Other Income for current quarter profitability
Significant change in business segment (Edible Oil to Solar)
Small equity base may lead to high volatility
👀 கவனிக்க வேண்டியவை
Investors should monitor the sustainability of the 'Renewable Energy' segment revenue and investigate the source of the high 'Other Income' which drove the quarterly profit. The shift in business focus from edible oils to solar cell products requires careful tracking of execution in the new sector.
Sarda Proteins Q1 Net Profit at ₹1.66 Cr; Revenue Grows 18.6% YoY to ₹12.99 Cr
Sarda Proteins reported a significant turnaround in Q1 FY27, posting a net profit of ₹165.97 Lakhs compared to a loss of ₹49.34 Lakhs in the same quarter last year. Revenue from operations grew 18.6% YoY to ₹1,299.30 Lakhs, while total revenue was further bolstered by a sharp increase in other income to ₹548.10 Lakhs. The company also announced the establishment of a new corporate office in Rajkot, Gujarat, and the appointment of an Independent Women Director. Notably, the company now identifies its primary segment as 'Renewable Energy Sector Solar Cell Products', indicating a shift from its historical edible oil focus.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company returned to profitability in Q1 FY27 and expanded its administrative footprint with a new corporate office in Gujarat while confirming a business focus on solar cell products.
ஏன் இது முக்கியம்The turnaround and segment shift suggest a major change in business strategy; however, the high reliance on other income for the bottom line warrants caution regarding core operational strength.
📅 குறுகிய காலம்The stock may see positive sentiment due to the turnaround from a loss to a profit and double-digit revenue growth.
📈 நீண்ட காலம்The structural shift to the renewable energy sector is significant; long-term value will depend on the company's ability to scale this new segment profitably.
⚠ அபாய எச்சரிக்கைகள்
High reliance on Other Income for current profit
Business segment shift risk
Limited historical data on the new solar cell segment
👀 கவனிக்க வேண்டியவை
Investors should monitor the sustainability of the new 'Renewable Energy Sector Solar Cell Products' segment and investigate the source of the high 'Other Income' which contributed significantly to this quarter's profit.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
